h eterozygous familial hypercholesterolemia (FH) affects up to 1.5 million individuals in the United States, with an estimated prevalence of 1 in 250 to 1 in 200. [1] [2] [3] Importantly, for those who are recognized and treated, statin use is associated with significantly decreased atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality. [4] [5] [6] [7] However, it is estimated that <1% of FH cases in the United States have been diagnosed, 7 and suboptimal treatment is common worldwide. 2, 8, 9 The burden of ASCVD associated with undiagnosed or undertreated FH in the general US population is unknown.
Available ASCVD risk calculators specifically exclude FH patients because participants with FH are uncommon in the community-based samples of asymptomatic, middle-aged individuals commonly used for derivation of risk equations. Therefore, the equations cannot account for the lifetime exposure to extreme low-density lipoprotein cholesterol (LDL-C) levels that FH patients experience. 10 Several prior reports have estimated ASCVD risk in untreated FH, 4, 7, [11] [12] [13] [14] [15] [16] [17] [18] but various methodological factors limit their application when considering FH patients in the general US population. 19 These studies have largely used non-US samples 4, 7, [12] [13] [14] [15] [16] [17] from referral-based clinic populations 4, 7, 14, 15 or a few kindred, [11] [12] [13] sometimes including those with prevalent ASCVD, 7, [14] [15] [16] [17] [18] and small outcome numbers have not allowed adjustment for known ASCVD risk factors. At present, US population-based data on long-term outcomes in FH are lacking, and a recent American Heart Association statement called for research that would more clearly define the natural history of this condition. 20 We therefore sought to quantify the long-term (up to 30 years) risks for coronary heart disease (CHD) and total ASCVD associated with an FH phenotype in the general US population, including younger and older adults. We defined the FH phenotype primarily by LDL-C levels ≥190 mg/dL, consistent with diagnostic criteria that maximize sensitivity. 14, [20] [21] [22] We pooled data from multiple large, population-based studies to ensure sufficient sample size for stable risk estimates. We hypothesized that compared with US adults with average LDL-C levels, those with an FH phenotype would have significantly increased hazards for CHD, even after adjustment for other risk factors, and that the hazards for CHD associated with the FH phenotype would be greatest at the youngest ages.
MethODs study Participants
Participants for this study were drawn from the Cardiovascular Lifetime Risk Pooling Project, which pools individual-level data from up to 22 large, population-based longitudinal cohort studies with at least 10 years of followup for cardiovascular disease (CVD) events. Details of the inclusion of cohorts and pooling and harmonization of data are presented elsewhere 23, 24 and summarized in Table  I in the online-only Data Supplement. Data sets from the Pooling Project that were included in the present analysis were required to have at least 1 baseline examination at which participants underwent direct measurement of serum lipids in addition to physiological and anthropometric variables. The following 6 cohorts were therefore selected: Framingham Heart Study (after 1968, when full lipid profile assessment began), 25 Framingham Offspring Study, 26 Cardiovascular Health Study, 27 ARIC study (Atherosclerosis Risk in Communities), 28 CARDIA study (Coronary Artery Risk Development in Young Adults), 29 and NHANES III (National Health and Nutrition Examination Survey III Mortality Study) 30, 31 (Table I in the online-only Data Supplement). Participants were excluded from the analysis if they had preexisting CVD (myocardial infarction [MI] , stroke, or heart failure) before the initial included examination or if they were missing serum lipid data. For the primary analysis, participants using cholesterol medication at the index age were included, but a sensitivity analysis evaluated the effect of excluding this group. This project was approved by the Institutional Review Board at Northwestern University.
clinical Perspective What is new?
• This is the first prospective evaluation of atherosclerotic cardiovascular disease outcomes for adults with heterozygous familial hypercholesterolemia in the general US population.
• Using individual pooled data from 6 epidemiological cohorts (68 565 baseline person-examinations and 1.2 million person-years of follow-up), we confirmed substantially elevated long-term (up to 30 years) risks for coronary heart disease and total atherosclerotic cardiovascular disease (including stroke) in US adults with a familial hypercholesterolemia phenotype, with acceleration of coronary heart disease risk by up to 20 to 30 years.
• The findings were independent of other risk factors and were consistent when various definitions of the familial hypercholesterolemia phenotype were used.
What are the clinical implications?
• Our results indicate that there is likely to be an important long-term burden of atherosclerotic cardiovascular disease in phenotypic but unrecognized familial hypercholesterolemia patients in the United States, and current efforts to identify patterns and gaps in diagnosis and management are well justified.
• Our findings on risk acceleration also have implications for risk communication in that clinicians can use our data to provide patients with a vivid, personalized risk message in the discussion about guideline-supported therapies.
lipid and covariate Measurements
Detailed protocols for lipid measurement and demographic and traditional risk factor assessment have been published for each cohort. [25] [26] [27] [28] [29] [30] Serum cholesterol levels, including total cholesterol (TC), triglycerides, and high-density lipoprotein cholesterol (HDL-C), were measured directly. LDL-C was calculated with the Friedewald equation for individuals with triglycerides <400 mg/dL. 32 Non-HDL-C was calculated as the difference between TC and HDL-C. Age, sex, race/ethnicity, smoking status, diabetes status, hypertension treatment, cholesterol treatment, and family history of CVD were determined by self-report. For these data, answers other than "yes" were assumed to be "no." Diabetes mellitus was also considered present if fasting blood sugar was ≥126 mg/dL or diabetes medication use was reported. Blood pressure was determined from the average of 2 to 3 measurements taken in participants while seated with a mercury sphygmomanometer.
Fh Phenotype and referent Definitions
We selected definitions of the FH phenotype that align with commonly used criteria to identify possible FH 14, 21, 22 and the simplified diagnostic criteria for FH proposed in the recent American Heart Association statement: LDL-C ≥190 mg/dL plus a first-degree relative with similar degree of hypercholesterolemia or with premature CHD. 20 For the primary analysis, we defined the FH phenotype simply as LDL-C ≥190 mg/ dL to maximize sensitivity for the condition, recognizing the limitations of self-reported family history data 9, 33 and challenges in harmonizing family history data between cohorts (Table I in the online-only Data Supplement). In a sensitivity analysis, we defined it as LDL-C ≥190 mg/dL plus a family history of CVD, that is, participant-reported history of CHD or stroke in either parent. In another sensitivity analysis, we restricted the definition further to require family history of premature CVD, that is, participant-reported first CHD incident or stroke at ≤55 or ≤60 years of age in the father or mother, respectively. These family history data were available only for CARDIA and ARIC participants (Table I in the online-only Data Supplement); thus, prevalence estimates involving family history include only these 2 cohorts. The referent group for these analyses was defined by LDL-C <130 mg/dL; this level is near recent US population means 34 and historically has been a target for primary prevention. The third (middle) group included all participants who met criteria for neither the FH phenotype nor referent group (ie, LDL-C 130-189 mg/dL for the primary analysis; LDL-C 130-189 mg/dL or negative/missing family history with LDL-C ≥190 mg/dL for the sensitivity analyses).
Additional sensitivity analyses were performed with varying definitions of the FH phenotype also used by expert panels, including MEDPED (Make Early Diagnosis to Prevent Early Death), 35 the Simon Broome Register, 14 and the National Lipid Association. 21 For the MEDPED analysis, age-based thresholds for the general population defined the FH phenotype for all participants: ≥220 mg/dL for 20 to 29 years of age, ≥240 mg/dL for 30 to 39 years of age, and ≥260 mg/ dL for 40 to 79 years of age. The referent was defined by LDL-C <130 mg/dL. The MEDPED criteria are expected to maximize specificity for molecular FH while sacrificing sensitivity (98% and 54% in the derivation sample, respectively). 35 For the TC-based analysis, the FH phenotype was defined by TC ≥290 mg/dL, with the additional requirement for positive family history in a further analysis. 14 The referent was TC <200 mg/dL. For the non-HDL-C-based analysis, the FH phenotype was defined by a composite of non-HDL-C ≥220 mg/dL or LDL-C ≥190 mg/dL, with the additional requirement for positive family history in a further analysis. 21 The referent was defined by non-HDL-C <220 mg/dL and LDL-C <130 mg/dL.
Outcome ascertainment
CHD events included CHD death and nonfatal MI. ASCVD events additionally included ischemic stroke. Events were ascertained according to each cohort's specific protocol. Except for NHANES III, all studies adjudicated fatal and nonfatal events using standardized clinical criteria. 27, 28, 36, 37 NHANES III ascertained CHD death and ASCVD death using International Classification of Diseases, Ninth Edition or 10th Edition, codes primarily from death certificate data through linkage to the National Death Index; nonfatal events were not ascertained. 31 
statistical analyses
To understand the effects of the FH phenotype on CVD outcomes across the life course, we examined 30-year risk from different index (baseline) ages: 20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69, and 70 to 79 years. Analyses were by person-examination (using the earliest study examination within the index age range) and were independent for each index age; thus, a given participant could contribute baseline and followup data for multiple index ages if he or she remained free of CVD and had lipids remeasured at the later ages. We stratified person-examinations into the 3 groups (FH phenotype, referent, and middle group) according to lipid levels (and family history). Available follow-up data were collected from the index examination until the occurrence of a first CVD event, death, or completion of 30 years. The date of last available follow-up data ranged from 1999 to 2010 for individual cohorts (Table I in the online-only Data Supplement).
We made comparisons across the 3 lipid groups for each index age. We compared baseline characteristics using general linear regression models for continuous variables and χ 2 tests for categorical variables. We assessed risk for the primary outcome of CHD death or nonfatal MI and secondary outcomes of CHD death alone and total ASCVD (including fatal/nonfatal stroke). CHD, rather than ASCVD, was chosen as the primary outcome because the data relating LDL-C to stroke are not consistent. 38 We calculated unadjusted event rates per 1000 person-years of follow-up for men and women separately. We used Cox proportional hazards regression to assess the association of the FH phenotype with outcome events, adjusting for cohort and for sex, age, race/ethnicity, body mass index, systolic blood pressure, hypertension treatment, cholesterol treatment, diabetes status, smoking status, and HDL-C level. We also generated Cox adjusted 30-year, event-free survival curves. We tested proportional hazards assumptions and found them to be appropriate. We examined the interactions of sex and race (black/nonblack) with LDL-C level on the outcome and found no significant interactions; we therefore present pooled sex-and race-adjusted results. However, we also performed Cox models separately by sex and race to examine whether patterns of association differed qualitatively. Finally, we calculated the proportion of incident CHD for the total cohort that would occur among those with the FH phenotype independently of other CVD risk factors: We multiplied the complement of the 30-year Cox adjusted survival probabilities (ie, the event probabilities) by the calculated prevalence of each LDL-C group, summed them to generate a weighted estimate of total event probability for the cohort, and divided the individual group CHD event estimates (ie, the product of prevalence and 30-year event probability) by this total event probability estimate to give the proportion of CHD occurring in that LDL-C group. For all comparisons, a 2-tailed value of P<0.05 was considered statistically significant. Statistical analyses were performed with SAS statistical software version 9.4 (SAS Institute, Inc), and the PROC PHREG procedure was used to compute Cox proportional hazard regression models.
resUlts

Participant characteristics
Baseline characteristics of the FH phenotype and referent groups stratified by index age are shown in Table 1 and  Table II in the online-only Data Supplement. (Table III in the online-only Data Supplement shows baseline characteristics separately by sex.) With the use of the primary definition, the FH phenotype (LDL-C ≥190 mg/dL) group contributed 3850 baseline person-examinations and made up 1.4% to 7.9% of the overall cohort at each index age. The prevalence most closely approached the reported FH prevalence of 0.4% to 0.5% at the youngest index ages but was substantially higher for older index ages. Across the index ages of the FH phenotype group, the mean LDL-C level was 210 to 214 mg/dL, and family history of CVD was reported in 33% to 46%. Compared with the referent group with LDL-C <130 mg/dL, those with the FH phenotype had a higher burden of other CVD risk factors on av- long-term chD risk associated With the Fh Phenotype, Defined by lDl-c ≥190 mg/dl Figure 1 shows the unadjusted event rates and underlying observed event numbers for men and women in the FH phenotype and referent groups across index ages. Unadjusted event rates were similar for men and women with the FH phenotype for the index age of 20 to 29 years, but for older index ages, the rates in men were almost double those in women. Conversely, age-based acceleration of CHD risk compared with the referent group was greater for women than for men. For men with the FH phenotype ( Figure 1A ), the event rates for each index age were generally equivalent to those for men with average LDL-C (ie, <130 mg/dL) who were 10 to 20 years older, indicating that CHD risk was accelerated by 10 to 20 years. For example, the event rate for 20-to 29-year-old men with the FH phenotype was 2.6 per 1000 personyears, which was equivalent to the rate for men between 30 to 39 years of age (1.5 per 1000 person-years) and 40 to 49 years of age (4.0 per 1000 person-years) with average LDL-C. A similar pattern was evident for women with the FH phenotype ( Figure 1B ), but for women, CHD risk was accelerated by 20 to 30 years. Table 2 (left) shows the hazards for CHD death or nonfatal MI associated with having the FH phenotype compared with an average LDL-C level after adjustment for cohort, sex, and baseline covariates. The hazards for CHD in the FH phenotype group were age dependent, with an up to 5-fold increased risk for the index age of 20 to 29 years, lower relative hazards at older ages, and a nonsignificant increase in risk for the index age of 70 to 79 years. Exclusion of participants taking cholesterol medication at baseline did not significantly affect the findings (results not shown). There was no significant interaction between sex and LDL-C level on the hazard ratios for the FH phenotype, but at younger index ages, hazard ratio point estimates were higher for women than for men ( Table 2 , right). There was also no significant interaction between race (black/nonblack) and LDL-C level on the hazard ratios, and hazard ratios were comparable between race groups (Table IV in the online-only Data Supplement). Figure 2 shows adjusted 30-year event-free survival curves for each index age. The survival curves for the FH phenotype group diverge progressively from those for the referent and middle groups, particularly for younger index ages.
secondary analyses: long-term risk for chD Death alone or total ascVD associated With the Fh Phenotype, Defined by lDl-c ≥190 mg/dl
In the analyses focusing on the outcomes of CHD death alone (Table V in the online-only Data Supplement) and total ASCVD (Table VI in the online-only Data Supplement), results approximated those for the primary outcome of CHD death or nonfatal MI. Hazard ratios were similar, Figure 1 . Unadjusted rates of coronary heart disease death or nonfatal myocardial infarction per 1000 personyears and underlying observed event numbers in (a) men and (B) women.
Unadjusted event rates are graphed by index age and low-density lipoprotein cholesterol (LDL-C) category; LDL-C ≥190 mg/dL represents the familial hypercholesterolemia (FH) phenotype, and LDL-C <130 mg/dL represents the referent. For men (a), event rates in the FH phenotype group at any given age are equivalent to those for men in the referent group who are 10 to 20 years older, indicating acceleration of coronary heart disease (CHD) risk by 10 to 20 years. For women (B), CHD risk is accelerated by 20 to 30 years. The tables below each graph show observed event numbers for the FH phenotype and referent groups by sex and index age. and the width of the confidence intervals varied with the numbers of observed events.
sensitivity analyses: Varying Definitions of the Fh Phenotype Table 3 shows observed CHD event numbers and adjusted hazard ratios related to having the FH phenotype, defined in various ways. When family history was added to the LDL-C-based definition, the FH phenotype prevalence (0.5%-3.3%) more closely approached the reported FH prevalence (0.4%-0.5%), and adjusted hazard ratios for CHD events approximated those in the primary analysis, with slightly higher point estimates but overlapping confidence intervals (Table 3) . When the FH phenotype definition was further restricted to require family history of premature CVD, the prevalence of this group declined further (0.1%-0.8%), but again, the pattern of CHD risk was unchanged (results not shown; too few events for stable risk estimates). When MEDPED LDL-C criteria were used to maximize the specificity for molecular FH, the prevalence of the FH phenotype was 0.2% to 0.4%. CHD risk was qualitatively more striking in this analysis, with higher hazard ratio point estimates and statistical significance for even the oldest index age; however, confidence intervals were wide and overlapped those for the primary analysis (Table 3) . When the FH phenotype was defined by alternative lipid fractions (TC or non-HDL-C), patterns were again unchanged (Table 3) .
Population impact: Proportion of total cohort chD related to the Fh Phenotype, Defined by lDl-c ≥190 mg/dl 
DiscUssiOn
This analysis provides novel information about the risks of CHD and total ASCVD (including stroke) associated with having the FH phenotype in a broad US populationbased sample. The principal finding is that the long-term CHD and ASCVD risks for US adults with the FH phenotype, defined simply by LDL-C ≥190 mg/dL, are substantially elevated (up to ≈5-fold) compared with those with average levels of LDL-C, even after adjustment for other CVD risk factors. This increased risk is age dependent, with the highest relative risks seen for younger index ages. Moreover, across the spectrum of baseline (index) ages, individuals with the FH phenotype experience an CHD indicates coronary heart disease; CI, confidence interval; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; and MI, myocardial infarction.
*Adjusted for age, race, body mass index, diabetes mellitus, smoking, systolic blood pressure, hypertension treatment, and cohort; data for the overall analysis have also been adjusted for sex, high-density lipoprotein cholesterol, and cholesterol treatment.
†Referent is (sex-specific) participants with LDL-C <130 mg/dL. ‡Proportion of total index age cohort 30-year CHD events projected to occur in the FH phenotype group. §Estimates may be unstable because of the small numbers of events. ¶P>0.05. 
Long-Term ASCVD Risk in FH
Findings in context
Prior reports have examined the natural history of FH in specific settings and found substantial, although variable, elevation of CHD and stroke risk, with risk patterns similar to those in the present analysis. For example, age dependency of risk has previously been observed in FH patients such as in the Simon Broome Register, 14 just as it is observed in the general population 38 (in which it probably reflects a higher genetic contribution to hypercholesterolemia that develops earlier in life). In the UK referral clinic patients in the Simon Broome Register, the overall risk for CHD death was 3.9 times that in the general population, but age-specific relative risk was 97 for 20 to 39 years of age and was not increased for ≥60 years of age. This age dependency is likely related to both accumulation of risk in the referent group with aging and survivor bias, with survival of lower-risk FH patients to older ages with the higher-risk patients having succumbed at younger ages. Similarly, acceleration of risk in FH patients has been observed previously. Stone et al Over 30 years of follow-up, event-free survival is progressively worse for the familial hypercholesterolemia (FH) phenotype group (low-density lipoprotein cholesterol [LDL-C] ≥190 mg/dL) than for the other 2 groups. Baseline mean±SD LDL-C levels for the LDL-C <130 mg/dL (referent), 130 to 189 mg/dL, and ≥190 mg/dL (FH phenotype) groups were (a) 20 to 29 years: 96±20, 148±15, and 213±38 mg/dL; (B) 30 to 39 years: 98±20, 150±15, and 210±24 mg/dL; (c) 40 to 49 years: 100±21, 152±16, and 213±28 mg/dL; (d) 50 to 59 years: 100±26, 154±16, and 214±25 mg/dL; (e) 60 to 69 years: 101±26, 154±16, and 213±27 mg/dL; and (F) 70 to 79 years: 100±25, 153±16, and 213±22 mg/dL, respectively. *Adjusted for age, sex, race, body mass index, diabetes mellitus, smoking, systolic blood pressure, antihypertensive therapy, high-density lipoprotein cholesterol, cholesterol treatment, and cohort. †Follow-up for index age of 70 to 79 years is truncated at 23 years because of insufficient sample size thereafter.
and Jensen et al 12 demonstrated acceleration of risk for MI or CHD death by 14 to 20 years in men and women with FH compared with unaffected relatives. Finally, Stone et al also found greater relative risks for women than for men, a finding that was suggested by our analysis, although it did not reach statistical significance. Notably, in both studies, the greater relative risks for women are observed despite higher absolute risks in men and therefore are largely a result of the lower-risk referent group in women compared with men.
The numeric risk estimates in this analysis differ from those in some prior reports, but when marked differences exist, they can likely be explained by differences in study methodology. For example, the Simon Broome report was based on a referral population in which 32% of participants had prevalent CVD at registration, and no adjustment was made for other CVD risk factors.
14 In contrast, the present analysis benefited from a large US population-based sample, including a substantial proportion of blacks, and risk estimates were fully adjusted. These are important distinctions because prior studies clearly indicate a wide range of CHD risk among those with FH, likely as a result of genetic factors and gene-environment interactions. 9, 11, 13 Our findings therefore may provide unique information about the burden of disease for the broader group with the FH phenotype, including those who remain undiagnosed.
limitations Some limitations to our study design may have led to underestimation of the risk for CHD and ASCVD in molecularly or clinically diagnosed FH. First, because our aim was to estimate risk related to FH in the general population, we had to rely on a "phenotype" rather than genetic diagnosis. Although we used criteria used clinically for diagnosis, we relied on a single LDL-C measurement, did not rule out secondary causes of hypercholesterolemia (eg, thyroid disease, nephrosis), and had limited family history data. Therefore, we almost certainly included some individuals with polygenic or secondary LDL-C elevation, as evidenced by a higher-than-expected prevalence of the FH phenotype (defined by LDL-C ≥190 mg/dL), especially at older ages. Importantly, when we required positive family history or used the stringent MEDPED LDL-C criteria to define the FH phenotype, the risk estimates did not change significantly, although power was limited. Second, although our results were unchanged after we excluded individuals using cholesterol-lowering medication at baseline, we could not identify or account for initiation CHD indicates coronary heart disease; CI, confidence interval; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; MEDPED, Make Early Diagnosis to Prevent Early Deaths; MI, myocardial infarction; and TC, total cholesterol. *Age based: ≥220 mg/dL (20-29 years of age), ≥240 mg/dL (30-39 years of age), and ≥260 mg/dL (40-79 years of age). †Adjusted for age, sex, race, body mass index, diabetes mellitus, smoking, systolic blood pressure, hypertension treatment, cholesterol treatment, and cohort; LDL-C and TC analyses also adjusted for HDL-C level. Referent groups are participants with LDL-C <130 mg/dL (LDL-C analyses), TC <200 mg/dL (TC analysis), and LDL-C <130 mg/dL and non-HDL-C <220 mg/dL (non-HDL-C analysis).
‡Estimates may be unstable because of the small numbers of events. §Hazard ratio estimate not reported as a result of a paucity of events. ¶P<0.05. implications
Long-Term ASCVD Risk in FH
The present study has important public health implications in that it confirms the substantial elevation in ASCVD risk for adults with the FH phenotype in a US populationbased sample. Notably, this is true even when the simple threshold of LDL-C ≥190 mg/dL is used to identify the FH phenotype, which provides support for the simplified FH diagnostic criteria proposed in the recent American Heart Association statement. 20 In combination with prior work suggesting the vast underdiagnosis of FH, 2,9 our data indicate that there is likely to be an important long-term burden of ASCVD in phenotypic but unrecognized FH patients in the United States. This is consistent with international reports that the prevalence of FH among young patients with MI may be many times higher than the prevalence of FH in the general population, from ≈2% to 4% of patients <60 years of age 3, 39 to almost 20% in patients <45 years of age. 39 In light of this amplification of FH prevalence among those with CHD, economic modeling in the United Kingdom has shown that identification and treatment of FH patients are not only cost-effective but cost-saving. 8 Several recent publications have emphasized the need for improved screening for and awareness and care of FH in the United States, 2, 8, 10, 20, 40 and through the ongoing CASCADE-FH registry (Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia), the FH foundation is working to identify patterns and gaps in diagnosis and management. 9 Our findings support the importance of this work.
Our data also have clinical implications for risk communication. Building on prior reports, we confirmed that FH patients not only have a higher risk for CHD but also have a shift in that risk toward younger ages. Clinicianpatient discussions about guideline-supported therapies can be informed by this information, as in the following scenario: A 25-year-old woman with newly diagnosed FH can be informed that at her current age, if her cholesterol were to remain untreated, her risk of CHD death or nonfatal MI is comparable to that for a 55-year-old woman. Such an analogy, paired with counseling about how to improve risk, may motivate behavioral changes and the adoption of and adherence to evidence-based medications. 41 
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Circulation is available at http://circ.ahajournals.org. 22-26 †Family history information is not released with the Framingham datasets. ‡For the present analysis, the definition of premature CVD was first CHD incident or stroke at age ≤55 years in the father (or ≤60 years in the mother); therefore positive paternal history of MI at age <60 years was not considered premature CVD. §Participants were asked, "Has either biological parent ever been told by a doctor that he or she had…. High blood pressure or stroke before the age of 50?
Heart attack or angina before the age of 50?" 25 Not compatible with family history definitions for the present analysis due to grouping of endpoints, lack of total (non-premature) family history data, and difference in age thresholds (<50 years) from those used for premature CVD in the present analysis (≤55 or ≤60 years in the father or mother, respectively).
||Participants were asked about the cardiovascular health histories of their siblings but not their parents. 7 Not compatible with family history definitions for the present analysis, which focused on parental history.
TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; MI, myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular disease. Table 1 ).
Supplemental
Continuous data presented as mean (SD), categorical data presented as N(%).
LDL, low-density lipoprotein; LDL-C, LDL cholesterol; FH, familial hypercholesterolemia; CVD, cardiovascular disease; HDL, high-density lipoprotein.
Supplemental Table 3 . Baseline characteristics of men and women with the familial hypercholesterolemia phenotype (LDL-C ≥190 mg/dL), by index age. Continuous data are presented as mean (SD), categorical data are presented as N(%).
LDL, low-density lipoprotein; LDL-C, LDL cholesterol; CHD, coronary heart disease; MI, myocardial infarction; HDL, high-density lipoprotein; CVD, cardiovascular disease.
Supplemental Table 4 . Race-specific familial hypercholesterolemia phenotype (defined by LDL-C≥190 mg/dL) prevalence and coronary heart disease death or nonfatal myocardial infarction at each index age. years also adjusted for high-density lipoprotein cholesterol level and cholesterol medication use. Referent is (race-specific) participants with LDL-C<130mg/dL. †Estimates may be unstable due to small numbers of events.
LDL-C, low-density lipoprotein cholesterol; FH, familial hypercholesterolemia; CHD, coronary heart disease; CI, confidence interval. and cohort. Referent is participants with LDL-C<130mg/dL. †Calcula ons based on small numbers of events; therefore, es mates may be unstable, and adjustment is not made for HDL-C or cholesterol medication.
LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol. 1-3 Importantly, for those who are recognized and treated, statin use is associated with significantly decreased atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality. [4] [5] [6] [7] However, it is estimated that <1% of FH cases in the United States have been diagnosed, 7 and suboptimal treatment is common worldwide. 2, 8, 9 The burden of ASCVD associated with undiagnosed or undertreated FH in the general US population is unknown.
Available ASCVD risk calculators specifically exclude FH patients because participants with FH are uncommon in the community-based samples of asymptomatic, middle-aged individuals commonly used for derivation of risk equations. Therefore, the equations cannot account for the lifetime exposure to extreme low-density lipoprotein cholesterol (LDL-C) levels that FH patients experience. 10 Several prior reports have estimated ASCVD risk in untreated FH, 4,7,11-18 but various methodological factors limit their application when considering FH patients in the general US population. 19 These studies have largely used non-US samples 4, 7, [12] [13] [14] [15] [16] [17] from referral-based clinic populations 4, 7, 14, 15 or a few kindred, [11] [12] [13] sometimes including those with prevalent ASCVD, 7, [14] [15] [16] [17] [18] and small outcome numbers have not allowed adjustment for known ASCVD risk factors. At present, US population-based data on long-term outcomes in FH are lacking, and a recent American Heart Association statement called for research that would more clearly define the natural history of this condition. 20 We therefore sought to quantify the long-term (up to 30 years) risks for coronary heart disease (CHD) and total ASCVD associated with an FH phenotype in the general US population, including younger and older adults. We defined the FH phenotype primarily by LDL-C levels ≥190 mg/dL, consistent with diagnostic criteria that maximize sensitivity. 14, [20] [21] [22] We pooled data from multiple large, population-based studies to ensure sufficient sample size for stable risk estimates. We hypothesized that compared with US adults with average LDL-C levels, those with an FH phenotype would have significantly increased hazards for CHD, even after adjustment for other risk factors, and that the hazards for CHD associated with the FH phenotype would be greatest at the youngest ages.
MethODs study Participants
clinical Perspective What is new?
130
Long-Term ASCVD Risk in FH Detailed protocols for lipid measurement and demographic and traditional risk factor assessment have been published for each cohort. [25] [26] [27] [28] [29] [30] Serum cholesterol levels, including total cholesterol (TC), triglycerides, and high-density lipoprotein cholesterol (HDL-C), were measured directly. LDL-C was calculated with the Friedewald equation for individuals with triglycerides <400 mg/dL. 32 Non-HDL-C was calculated as the difference between TC and HDL-C. Age, sex, race/ethnicity, smoking status, diabetes status, hypertension treatment, cholesterol treatment, and family history of CVD were determined by self-report. For these data, answers other than "yes" were assumed to be "no." Diabetes mellitus was also considered present if fasting blood sugar was ≥126 mg/dL or diabetes medication use was reported. Blood pressure was determined from the average of 2 to 3 measurements taken in participants while seated with a mercury sphygmomanometer.
Fh Phenotype and referent Definitions
Outcome ascertainment
CHD events included CHD death and nonfatal MI. ASCVD events additionally included ischemic stroke. Events were ascertained according to each cohort's specific protocol. Except for NHANES III, all studies adjudicated fatal and nonfatal events using standardized clinical criteria.
27,28,36,37 NHANES III ascertained CHD death and ASCVD death using International Classification of Diseases, Ninth Edition or 10th Edition, codes primarily from death certificate data through linkage to the National Death Index; nonfatal events were not ascertained. 31 Participants in NHANES III contributed 4.3% to 19.5% of the total baseline person-examinations at each index age 
statistical analyses
resUlts
Participant characteristics
Population impact: Proportion of total cohort chD related to the Fh Phenotype, Defined by lDl-c ≥190 mg/dl Table 2 also shows the proportion of incident CHD for the total cohort at each index age projected to occur in those with the FH phenotype independently of other CVD risk factors. For the combined group of men and women, that proportion is more than double the prevalence of the FH phenotype for younger index ages. The disproportionate CHD burden is more prominent for women than for men. For the index age of 20 to 29 years, 8.1% of CHD events in women would occur in the 1.4% of women with the FH phenotype, whereas 3.3% of CHD events in men would occur in the 1.5% of men with the FH phenotype.
DiscUssiOn
This analysis provides novel information about the risks of CHD and total ASCVD (including stroke) associated with having the FH phenotype in a broad US populationbased sample. The principal finding is that the long-term CHD and ASCVD risks for US adults with the FH phenotype, defined simply by LDL-C ≥190 mg/dL, are substantially elevated (up to ≈5-fold) compared with those with average levels of LDL-C, even after adjustment for other CVD risk factors. This increased risk is age dependent, with the highest relative risks seen for younger index ages. Moreover, across the spectrum of baseline (index) ages, individuals with the FH phenotype experience an 
Findings in context
limitations Some limitations to our study design may have led to underestimation of the risk for CHD and ASCVD in molecularly or clinically diagnosed FH. First, because our aim was to estimate risk related to FH in the general population, we had to rely on a "phenotype" rather than genetic diagnosis. Although we used criteria used clinically for diagnosis, we relied on a single LDL-C measurement, did not rule out secondary causes of hypercholesterolemia (eg, thyroid disease, nephrosis), and had limited family history data. Therefore, we almost certainly included some individuals with polygenic or secondary LDL-C elevation, as evidenced by a higher-than-expected prevalence of the FH phenotype (defined by LDL-C ≥190 mg/dL), especially at older ages. Importantly, when we required positive family history or used the stringent MEDPED LDL-C criteria to define the FH phenotype, the risk estimates did not change significantly, although power was limited. Second, although our results were unchanged after we excluded individuals using cholesterol-lowering medication at baseline, we could not identify or account for initiation 
implications
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